Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11414708B2 · kind B2 · utility
0Cited by
124References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2017 |
| Grant date | Aug 16, 2022 |
| Priority date | — |
| Expiry date | Jul 24, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A90/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.